Functions of RANKL/RANK/OPG in bone modeling and remodeling

被引:1877
作者
Boyce, Brendan F. [1 ]
Xing, Lianping [1 ]
机构
[1] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA
关键词
bone resorption; osteoclasts; RANKL; RANK; OPG;
D O I
10.1016/j.abb.2008.03.018
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
The discovery of the RANKL/RANK/OPG system in the mid 1990s for the regulation of bone resorption has led to major advances in our understanding of how bone modeling and remodeling are regulated. It had been known for many years before this discovery that osteoblastic Stromal cells regulated osteoclast formation, but it had not been anticipated that they would do this through expression of members of the TNF superfamily: receptor activator of NF-kappa B ligand (RANKL) and osteoprotegerin (OPG), or that these cytokines and signaling through receptor activator of NF-kappa B (RANK) would have extensive functions beyond regulation of bone remodeling. RANKL/RANK signaling regulates osteoclast formation, activation and survival in normal bone modeling and remodeling and in a variety of pathologic conditions characterized by increased bone turnover. OPG Protects bone from excessive resorption by binding to RANKL and preventing it from binding to RANK. Thus, the relative concentration of RANKL and OPG in bone is a major determinant of bone mass and strength. Here, we review our current understanding of the role of the RANKL/RANK/OPG system in bone modeling and remodeling. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:139 / 146
页数:8
相关论文
共 108 条
[1]
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function [J].
Anderson, DM ;
Maraskovsky, E ;
Billingsley, WL ;
Dougall, WC ;
Tometsko, ME ;
Roux, ER ;
Teepe, MC ;
DuBose, RF ;
Cosman, D ;
Galibert, L .
NATURE, 1997, 390 (6656) :175-179
[2]
[Anonymous], NAT MED
[3]
Autoamplification of NFATc1 expression determines its essential role in bone homeostasis [J].
Asagiri, M ;
Sato, K ;
Usami, T ;
Ochi, S ;
Nishina, H ;
Yoshida, H ;
Morita, I ;
Wagner, EF ;
Mak, TW ;
Serfling, E ;
Takayanagi, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (09) :1261-1269
[4]
BAI S, 2007, J BIOL CHEM
[5]
The effect of a single dose of osteoprotegerin in postmenopausal women [J].
Bekker, PJ ;
Holloway, D ;
Nakanishi, A ;
Arrighi, M ;
Leese, PT ;
Dunstan, CR .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (02) :348-360
[6]
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women [J].
Bekker, PJ ;
Holloway, DL ;
Rasmussen, AS ;
Murphy, R ;
Martin, SW ;
Leese, PT ;
Holmes, GB ;
Dunstan, CR ;
DePaoli, AM .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (07) :1059-1066
[7]
Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice [J].
Bennett, Brian J. ;
Scatena, Marta ;
Kirk, Elizabeth A. ;
Rattazzi, Marcello ;
Varon, Rebecca M. ;
Averill, Michelle ;
Schwartz, Stephen M. ;
Giachelli, Cecilia M. ;
Rosenfeld, Michael E. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (09) :2117-2124
[8]
Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis [J].
Blair, JM ;
Zhou, H ;
Seibel, MJ ;
Dunstan, CR .
NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (01) :41-49
[9]
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases [J].
Body, JJ ;
Greipp, P ;
Coleman, RE ;
Facon, T ;
Geurs, F ;
Fermand, JP ;
Harousseau, JL ;
Lipton, A ;
Mariette, X ;
Williams, CD ;
Nakanishi, A ;
Holloway, D ;
Martin, SW ;
Dunstan, CR ;
Bekker, PJ .
CANCER, 2003, 97 (03) :887-892
[10]
Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases [J].
Boyce, BF ;
Xing, LP ;
Shakespeare, W ;
Wang, YH ;
Dalgarno, D ;
Iuliucci, J ;
Sawyer, T .
KIDNEY INTERNATIONAL, 2003, 63 :S2-S5